Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Phase 2 Completed 30 enrolled Chinese PLA General Hospital

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of venetoclax combined with CACAG regimen in the treatment of newly diagnosed acute myeloid leukemia.

Timeline

Start: 2022-12-25
Primary completion: 2023-08-14
Completion: 2024-08-14

Publications

Liu Q, Yang J, Lv L, Zhang X, Li M, Xu L, Huang S, Jing Y, Dou L. Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia. Front Immunol. 2025 Feb 26;16:1525110. doi: 10.3389/fimmu.2025.1525110. eCollection 2025.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aclamycin	Unknown	10 mg/m2	—
Subject	Azacitidine	Other / unclassified	75 mg/m2	—
Subject	Cytarabine	Small molecule	75 mg/m2	—
Subject	Tucidinostat	Small molecule	30 mg	—
Subject	Venetoclax	Small molecule	400 mg	—

Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Summary

Timeline

Publications

Drugs

Indications